Minisymposium: Biologics – making it your business



About the Symposium

The discovery and development of biologicals represent a major challenge and requires a unique set of skills and capabilities. For a start-up or academic group looking to develop a new drug it can be difficult to navigate this territory and to avoid potential pitfalls. This one-day symposium seeks to provide insights to the area by inviting speakers who have taken biological drugs from the lab into the clinic, in addition to introducing specialists with expertise in some of the capabilities required.

 

Program

09.30 Registration and coffee
 –
10:00 Welcome
10:10 Biologics – from academic idea to clinic
Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, ETH Zurich
10.55 ADC-1013, an agonistic CD40 antibody – from PhD-project to clinical development
Peter Ellmark, PhD, Assoc Prof, Principal Scientist, Alligator Bioscience AB
11.40 Lunch
12.40 Development of Biologics: Case study – Lysosomal Storage Diseases and Enzyme Replacement Therapies
Claes Andersson, PhD, Research Director Zymenex A/S
13.25 Biologics – Assessment of immunotoxicity
Karin Cederbrant, PhD, Assoc prof, Specialist in vitro-metodhology and immunotoxicology
14.10 Drug substance for Toxicology Studies and Phase 1 clinical trials – How to make it happen
Robert Björnestedt, PhD, Project Manager, Cobra Biologics
14.45 Coffee break
15.15 Using Protein Engineering to Create Differentiated Biopharmaceutical Products.
General Impressions and the Sobi Experience
Patrik Strömberg, PhD, Senior Director R&D, Swedish Orphan Biovitrum AB (SOBI)
15.50 Closing

 Please select a valid form